Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1

被引:14
作者
DuHadaway, JB
Du, W
Donover, S
Baker, J
Liu, AX
Sharp, DM
Muller, AJ
Prendergast, GC
机构
[1] Lankenau Inst Med Res, Wynnewood, PA 19096 USA
[2] DuPont Pharmaceut Co, Canc Res Grp, Glenolden, PA USA
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[4] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA
关键词
FTI; farnesyltransferase; Ras; RhoB; SV40T antigen; amphiphysin;
D O I
10.1038/sj.onc.1206481
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neoplastic transformation sensitizes many cells to apoptosis. This phenomenon may underlie the therapeutic benefit of many anticancer drugs, but its molecular basis is poorly understood. We have used a selective and potent farnesyltransferase inhibitor (FTI) to probe a mechanism of apoptosis that is peculiarly linked to neoplastic transformation. While nontoxic to untransformed mouse cells, FTI triggers a massive RhoB-dependent, p53-independent apoptosis in mouse cells that are neoplastically transformed. Here we offer evidence that the BAR adapter-encoding tumor suppressor gene Bin1 is required for this transformation-selective death program. Targeted deletion of Bin1 in primary mouse embyro fibroblasts (MEFs) transformed by E1A + Ras did not affect FTI-induced reversion, actin fiber formation, or growth inhibition, but it abolished FTI-induced apoptosis. The previously defined requirement for RhoB in these effects suggests that BinI adapter proteins act downstream or in parallel to RhoB in cell death signaling. The death defect in Bin1 null cells was significant insofar as it abolished FTI efficacy in tumor xenograft assays. p53 deletion did not phenocopy the effects of Bin1 deletion. However, MEFs transformed by SV40 large T antigen + Ras were also resistant to apoptosis by FTI, consistent with other evidence that large T inhibits Bin1-dependent cell death by a p53-independent mechanism. Taken together, the results define a function for Bin1 in apoptosis that is conditional on transformation stress. This study advances understanding of the functions of BAR adapter proteins, which are poorly understood, by revealing genetic interactions with an Rho small GTPase that functions in stress signaling. The frequent losses of Bin1 expression that occur in human breast and prostate cancers may promote tumor progression and limit susceptibility to FTI or other therapeutic agents that exploit the heightened sensitivity of neoplastic cells to apoptosis.
引用
收藏
页码:3578 / 3588
页数:11
相关论文
共 57 条
[1]   INTRACELLULAR-LOCALIZATION OF THE P21(RHO) PROTEINS [J].
ADAMSON, P ;
PATERSON, HF ;
HALL, A .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :617-627
[2]   DEFINING PROTEIN INTERACTIONS WITH YEAST ACTIN IN-VIVO [J].
AMBERG, DC ;
BASART, E ;
BOTSTEIN, D .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (01) :28-35
[3]  
Balguerie A, 1999, J CELL SCI, V112, P2529
[4]   A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis [J].
Barrington, RE ;
Subler, MA ;
Rands, E ;
Omer, CA ;
Miller, PJ ;
Hundley, JE ;
Koester, SK ;
Troyer, DA ;
Bearss, DJ ;
Conner, MW ;
Gibbs, JB ;
Hamilton, K ;
Koblan, KS ;
Mosser, SD ;
O'Neill, TJ ;
Schaber, MD ;
Senderak, ET ;
Windle, JJ ;
Oliff, A ;
Kohl, NE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :85-92
[5]   ALTERATION OF A YEAST SH3 PROTEIN LEADS TO CONDITIONAL VIABILITY WITH DEFECTS IN CYTOSKELETAL AND BUDDING PATTERNS [J].
BAUER, F ;
URDACI, M ;
AIGLE, M ;
CROUZET, M .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (08) :5070-5084
[6]  
Bon E, 2000, YEAST, V16, P1229, DOI 10.1002/1097-0061(20000930)16:13<1229::AID-YEA618>3.0.CO
[7]  
2-Q
[8]   Genetic and functional relationship between Rvsp, myosin and actin in Saccharomyces cerevisiae [J].
Breton, AM ;
Aigle, M .
CURRENT GENETICS, 1998, 34 (04) :280-286
[9]  
Colwill K, 1999, GENETICS, V152, P881
[10]   Farnesyltransferase inhibitors - Potential role in the treatment of cancer [J].
Cox, AD .
DRUGS, 2001, 61 (06) :723-732